Skip to main content

Table 5 Clinicopathologic characteristics

From: Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study

CharacteristicWithout postoperative chemotherapy
(n = 112)
With postoperative chemotherapy
(n = 15)
P
Age (years)56.19 ± 9.7955.13 ± 7.940.690
Male59 (52.7)10 (66.7)0.307
Location  0.203
Hilar18 (16.1)5 (33.3) 
Peripheral94 (83.9)10 (66.7) 
HBsAg  0.494
 Negative81 (72.3)9 (60.0) 
 Positive31 (27.7)6 (40.0) 
Tumor size (cm)  0.110
  ≤ 543 (38.4)9 (60.0) 
  > 569 (61.6)6 (40.0) 
Multiple tumor  0.315
 No79 (70.5)13 (86.7) 
 Yes33 (29.5)2 (13.3) 
Vascular invasion  0.538
 No69 (61.6)8 (53.3) 
 Yes43 (38.4)7 (46.7) 
Capsular invasion  0.371
 No61 (54.5)10 (66.7) 
 Yes51 (45.5)5 (33.3) 
Visceral invasion  0.127
 No90 (80.4)15 (100.0) 
 Yes22 (19.6)0 (0.0) 
AJCC T stage  0.250
 1 and 257 (50.9)10 (66.7) 
 3 and 455 (49.1)5 (33.3) 
AJCC N stage  0.967
 074 (66.1)10 (66.7) 
 125 (22.3)3 (20.0) 
 x13 (11.6)2 (13.3) 
AJCC tumor stage  0.364
 I28 (25.0)6 (40.0) 
 II18 (16.1)1 (6.7) 
 III66 (58.9)8 (53.3) 
Tumor differentiation  0.643
 Well to moderate38 (33.9)6 (40.0) 
 Poor to undifferentiated74 (66.1)9 (60.0) 
Liver cirrhosis  0.450
 No71 (63.4)11 (73.3) 
 Yes41 (36.6)4 (26.7) 
ALT (U/L)  0.163
  ≤ 4073 (65.2)7 (46.7) 
  > 4039 (34.8)8 (53.3) 
AST (U/L)  0.297
  ≤ 4075 (67.0)8 (53.3) 
  > 4037 (33.0)7 (46.7) 
PLT (×10^9/L)232.32 ± 94.43208.60 ± 87.960.359
CEA (ng/ml)  0.859
  ≤ 583 (74.1)12 (80.0) 
  > 529 (25.9)3 (20.0) 
CA19–9 (U/ml)  0.482
  ≤ 20064 (57.1)10 (66.7) 
  > 20048 (42.9)5 (33.3) 
CA242 (U/ml)  0.910
  ≤ 2058 (51.8)8 (53.3) 
  > 2054 (48.2)7 (46.7) 
Child-Pugh score  0.228
 A99 (88.4)11 (73.3) 
 B13 (11.6)4 (26.7) 
Perineural invasion  0.482
 No64 (57.1)10 (66.7) 
 Yes48 (42.9)5 (33.3) 
Post-recurrence anti-tumor therapy  0.489
 Yes72 (64.3)11 (73.3) 
 No40 (35.7)4 (26.7) 
  1. Data are expressed as mean ± standard deviation or n (%)
  2. PNI perineural invasion, HBsAg hepatitis B surface antigen, AJCC American Joint Committee on Cancer, ALT Alanine aminotransferase, AST Aspartate aminotransferase, PLT Blood platelet, CEA Carcinoembryonic antigen